A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

Summary

To evaluate the efficacy, safety and tolerability of multiple doses of QBW251 vs placebo administered orally, on airway function, lung volume, and quality of life in patients with chronic obstructive pulmonary disease (COPD)

Timeline

Start

2015-04-30

Primary completion

2016-12-27

Completion

2017-01-23

Outcome

Missed primary endpoint

registry analysis (superiority test); QBW251 vs Placebo; p = 0.130; Mean Difference (Net) 0.28 (90% CI -0.24 to 0.79); ANCOVA NCT02449018 ↗

Drugs

Indications